In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tianjin KingYork Group Co. Ltd.

Latest From Tianjin KingYork Group Co. Ltd.

Deals In Depth: May 2013

AbbVie paid $70 million up front in an option-based deal with Alvine, and both Valeant and Actavis completed $8 billion-plus acquisitions, of B&L and Warner Chilcott, respectively. IPOs accounted for $1 billion of the $2.7 billion in biopharma financing; device firms raised $342 million.

BioPharmaceutical Medical Device

Deals Shaping The Medical Industry, July 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Pharmaceuticals